Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: Medicine ; Cancer Research ; Biomedicine ; Cancer Research ; Springer eBooks
    Description / Table of Contents: Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? -- Resistance to HER2-targeted therapy -- Endocrine Resistance and Breast Cancer Stem Cells – The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes -- EGFR Resistance -- Targeting FGFR for the treatment of breast cancer -- Targeted Therapies in Breast Cancer -- Future paradigm of breast cancer resistance and treatment
    Abstract: We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy. ℗
    Pages: XV, 184 p. 12 illus. in color. : online resource.
    ISBN: 9783319701424
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: Medicine ; Oncology ; Immunology ; Monoclonal antibodies ; Biomedicine ; Cancer Research ; Molecular Medicine ; Immunology ; Antibodies ; Springer eBooks
    Description / Table of Contents: Preface -- Introduction and generation of chimeric and humanized mAbs -- mAbs targeted against cancer cells and antibodies targeted against the tumor microenvironment -- Antibodies directed against different major cancers: Effects when used ℗ alone or in combination with drugs -- Mechanisms of antibodies-mediated responses, in vitro and in vivo -- Molecular Pathways -- Molecular Signatures -- Identification of resistance targets for intervention -- Various chemicals that can sensitize resistant tumor cells -- Other mAbs -- Proteasome inhibitors -- Divalent mAbs -- Antibodies coupled to chemical inhibitors -- Antibodies coupled to cytokines -- Nanoparticles with mAbs -- Index
    Abstract: The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance. Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs
    Pages: XIII, 202 p. 29 illus., 15 illus. in color. : online resource.
    ISBN: 9781461476542
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Keywords: Medicine ; Cancer Research ; Biomedicine ; Cancer Research ; Springer eBooks
    Description / Table of Contents: Targeted therapies in gliomas: An overview -- Targeting chemotherapy resistance in glioblastoma through modulation of ABC transporters -- Resistance of Glioblastomas to Radiation Therapy -- The blood-brain barrier in glioblastoma multiforme: Pathology and therapeutic implications -- Resistance of brain tumours to small-molecule targeted therapies: lessons from various cancer types -- Drug repurposing to circumvent chemotherapy resistance in brain tumours -- Small molecule inhibitors in glioblastoma: Key pathways and resistance mechanisms -- Imaging Targeted Therapy Response and Resistance in Glioblastoma -- Drug Resistance in Malignant Meningiomas -- Recurrence of Low-Grade Glioma - Have the Targeted Therapies Improved for Better Outcomes? -- Host-Tumor Interactions in Brain Cancer Metastasis Leading to Drug Resistance
    Abstract: This volume will bring together a review of research being carried out by international experts in this field, detailing treatment and research approaches in several forms of malignant brain tumors. These include glioblastoma (GBM), a highly aggressive and fatal form of astrocytoma which accounts for 80% of newly diagnosed brain tumor patients per year, and meningioma, of which 10% are malignant and extremely resistant to targeted therapies. The volume will also include a discussion of methods to overcome blood-brain barrier exclusion for more efficient targeted drug delivery in all forms of brain cancer treatment. The volume will include information on the repurposing of drugs in an attempt to circumvent drug resistance, use of small molecule inhibitors in GBM treatment, mechanisms of secondary brain metastasis, drug resistance, and state-of-the-art imaging of targeted therapies
    Pages: XVI, 260 p. 19 illus., 16 illus. in color. : online resource.
    ISBN: 9783319465050
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    facet.materialart.
    Cham : Springer International Publishing
    Keywords: Medicine ; Cancer Research ; Biomedicine ; Cancer Research ; Springer eBooks
    Description / Table of Contents: Tyrosine Kinase Signaling Pathways in Normal and Cancer Cells -- Resistance to Tyrosine Kinase Inhibitors in different types of solid cancer -- The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview -- Resistance to FLT3 Inhibitors -- Resistance to ALK inhibitors -- Resistance to Angiokinase Inhibitors -- Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors
    Abstract: The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors
    Pages: XIII, 188 p. 8 illus., 6 illus. in color. : online resource.
    ISBN: 9783319460918
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    Keywords: Medicine ; Cancer Research ; Biomedicine ; Cancer Research ; Springer eBooks
    Description / Table of Contents: Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma -- Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma -- Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance -- Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance -- Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma -- Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma -- Sorafenib and Clinical Patterns of Resistance in hepatocellular carcinoma -- Overcoming Treatment Resistance in Hepatocellular Carcinoma: regorafenib and lessons from other malignancies
    Abstract: This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies
    Pages: XIII, 147 p. 16 illus. in color. : online resource.
    ISBN: 9783319561974
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    Keywords: Medicine ; Oncology ; Drug Interactions ; Biomedicine ; Cancer Research ; Drug Resistance ; Molecular Medicine ; Springer eBooks
    Description / Table of Contents: Role of P-glycoprotein for resistance of tumors to anticancer drugs: From bench to bedside -- Clinical relevance of multidrug-resistance-related proteins (MRPs) for anticancer drug resistance and prognosis -- Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance -- A new strategy of ALA-photodynamic cancer therapy: Inhibition of ABC transporter ABCG2 -- ABC transporters in cancer stem-like cells -- Radiopharmaceuticals for the imaging of ABC-transporter-mediated multidrug resistance in cancer -- Modulation of P-glycoprotein-mediated multidrug resistance by synthetic and phytochemical small molecules, monoclonal antibodies and therapeutic nucleic acids -- ABC transporter modulatory drugs from marine sources: A new approach to overcome drug resistance in cancer -- The role of ABC multidrug transporters in resistance to targeted anti-cancer kinase inhibitors -- Nanotechnology to combat multidrug resistance in cancer -- Drugs affecting epigenetic modifications of ABC transporters
    Abstract: This volume covers the most current topics relevant to ABC transporters and resistance to novel and established anticancer drugs, prognosis of patients to compounds to modulate multidrug resistance, compounds used in photodynamic therapy, tyrosine kinase inhibitors and others. Furthermore, the potential of radiopharmaceuticals for diagnosis of multidrug-resistant tumors is also discussed. The development of resistance is a major obstacle in cancer chemotherapy since decades. Drug resistance may develop during repeated treatment cycles after initially successful therapy (acquired or secondary resistance). Alternatively, tumors may be resistant from the beginning (inherent or primary resistance). The failure of chemotherapy is a major reason for the fatal outcome of tumor diseases in many patients. Even worse, tumors frequently develop not only resistance to single drugs, but also to many others at the same time. This phenomenon was termed multidrug resistance and decreases the success rates of therapy regimens with combinations of structurally and functionally different drugs. The uncommonly broad spectrum of anticancer agents that are transported by ABC transporters makes these proteins exquisite targets to search for compounds that inhibit their transport function. A huge amount of compounds from many pharmacologically established drug were observed to inhibit ABC transporters and to reverse multidrug resistance€”áll of these topics and more is explored in this volume
    Pages: X, 300 p. 60 illus., 21 illus. in color. : online resource.
    ISBN: 9783319098012
    Signatur Availability
    BibTip Others were also interested in ...
  • 7
    Keywords: Medicine ; Oncology ; Drug Interactions ; Biomedicine ; Cancer Research ; Drug Resistance ; Molecular Medicine ; Springer eBooks
    Description / Table of Contents: Basic and Clinical Aspects of photodynamic Therapy -- Mechanisms of Resistance to Photodynamic Therapy -- Tumor Vascular Microenvironment Determines responsiveness to Photodynamic Therapy -- Autophagy Pathways Activated in Response to PDT Contribute to Cell Resistance Against ROS Damage -- Methods to isolate the Resistant Cells to Photodynamic Therapy -- GRP78-Targeting Subtilase Cytotoxin Sensitizes Cancer Cells to Photodynamic Therapy -- Optimization of Photodynamic Therapy Response by Survivin Gene Knockdown in Human Metastatic Breast Cancer -- Cellular Targets and Molecular Responses Associated with Photodynamic Therapy -- The Use of Nanoparticle-Delivered Photosensitizers Can Overcome the Development of Resistance to PDT in Tumors -- Mechanisms of tumor cells resistance to ALA/PDT -- Overcoming the Resistance of Meolanoma to Photodynamic Therapy
    Abstract: This volume provides a comprehensive review of resistance induced by photodynamic therapy (PDT) in tumor cells. Understanding the underlying mechanisms in this process leads to the improvement of therapeutic modality, in combination with chemotherapy, immunotherapy, and radiotherapy. Photodynamic therapy is a minimally invasive therapeutic procedure that can exert a selective or preferential cytotoxic activity toward malignant cells. The procedure involves administration of an intrinsically non-toxic photosensitizing agent (PS) followed by irradiation at a wavelength corresponding to a visible absorption band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Studies reveal that PDT can be curative, particularly in early stage tumors and this volume explores the potential of PDT, but also reveals strategic approaches to overcome resistance in tumor cells
    Pages: XIII, 248 p. 48 illus., 36 illus. in color. : online resource.
    ISBN: 9783319127309
    Signatur Availability
    BibTip Others were also interested in ...
  • 8
    facet.materialart.
    Cham : Springer International Publishing
    Keywords: Medicine ; Cancer Research ; Biomedicine ; Cancer Research ; Springer eBooks
    Description / Table of Contents: Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer -- TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer -- IAPs and Resistance to Death Receptors in Cancer -- Bcl-2 Proteins and TRAIL Resistance in Melanoma -- Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4 -- Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy -- Atypical Immune Functions of CD95/CD95L -- TLR3 is a Death Receptor Target in Cancer Therapy -- Fas/CD95, Lipid Rafts and Cancer -- Role of Sphingolipids in Death Receptor Signalling -- Post-Translational Modifications and Death Receptor Signalling -- System Modeling of Receptor-Induced Apoptosis
    Abstract: This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors
    Pages: XIII, 317 p. 40 illus., 35 illus. in color. : online resource.
    ISBN: 9783319568058
    Signatur Availability
    BibTip Others were also interested in ...
  • 9
    Keywords: Medicine ; Oncology ; Drug Interactions ; Biomedicine ; Cancer Research ; Drug Resistance ; Molecular Medicine ; Springer eBooks
    Abstract: This book, written by leading investigators, brings together the latest knowledge about key aspects of the most rapidly progressing fields of tumor escape and tumor resistance to CTL. Readers will benefit from a collection of outstanding surveys that cover some factors regulating resistance to CTL cytotoxicity, the influence of tumor microenvironment, and the resistance to death ligands, mediated apoptosis, and means to reverse resistance. This remarkable volume also emphasizes the future directions that may lead to the design of more innovative, refined, ℗ and integrative immunotherapies to target tumor plasticity and heterogeneity, and help to overcome the inherent limitations of current treatments. By providing a broad scope of innovative concepts in the burgeoning field of cancer biology and immunotherapy, this volume will be of exceptional interest and a valuable reference for scientists, clinicians, health professionals, and biopharmaceutical companies working in the field of cancer immunotherapy. ℗
    Pages: XIV, 353 p. 38 illus., 27 illus. in color. : online resource.
    ISBN: 9783319178073
    Signatur Availability
    BibTip Others were also interested in ...
  • 10
    Keywords: Medicine ; Cancer Research ; Molecular Biology ; Biomedicine ; Cancer Research ; Molecular Medicine ; Springer eBooks
    Description / Table of Contents: Chapter 1 BTK inhibitors: focus on ibrutinib and similar agents -- Chapter 2 BCL2 Inhibitors: insights into resistance -- Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib -- Chapter 4 IMiD – immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms -- Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents -- Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents
    Abstract: In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.℗
    Pages: XIII, 138 p. 14 illus., 13 illus. in color. : online resource.
    ISBN: 9783319751849
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...